严重哮喘,生物过敏和无效:克服tezepelumab的治疗障碍。

IF 1.3 4区 医学 Q3 ALLERGY
Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes
{"title":"严重哮喘,生物过敏和无效:克服tezepelumab的治疗障碍。","authors":"Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes","doi":"10.1080/02770903.2025.2552744","DOIUrl":null,"url":null,"abstract":"<p><p>Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.</p><p><p>We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-5"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Severe asthma, biologic hypersensitivity and inefficacy: overcoming treatment barriers with tezepelumab.\",\"authors\":\"Maria Bragança, Inês Barreto, Henrique Rodrigues, Ana Mendes, Carlos Lopes\",\"doi\":\"10.1080/02770903.2025.2552744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.</p><p><p>We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.</p>\",\"PeriodicalId\":15076,\"journal\":{\"name\":\"Journal of Asthma\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02770903.2025.2552744\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2552744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

严重哮喘是一种涉及多种炎症途径的异质性疾病,具有重大的治疗挑战。针对T2炎症的生物治疗可改善预后,但在极少数情况下,可能会因抗药物抗体、辅料或蛋白质结构而引发过敏反应。此外,一些患者表现出次优或无反应。Tezepelumab是一种胸腺基质淋巴生成素抑制剂,提供了一种新颖的上游方法,可解决多种内质类型。我们报告一位30岁女性,患有严重的t2 -高哮喘,多重过敏,尽管有最佳治疗,但疾病控制不佳。她对奥玛单抗和杜匹单抗有过敏反应,对苯那利单抗反应不足。在tezepelumab的早期准入项目中,她表现出显著的临床改善,FEV1显著增加,FeNO显著降低,允许停止全身皮质类固醇和补充氧气。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Severe asthma, biologic hypersensitivity and inefficacy: overcoming treatment barriers with tezepelumab.

Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to anti-drug antibodies, excipients, or protein structure. Additionally, some patients exhibit suboptimal or no response. Tezepelumab, a thymic stromal lymphopoietin inhibitor, offers a novel upstream approach, addressing diverse endotypes.

We present a 30-year-old female with severe T2-high asthma, multiple allergies, and poor disease control despite optimal therapy. She experienced an allergic reaction with omalizumab and dupilumab and had inadequate response to benralizumab. Enrolled in an early access program for tezepelumab, she showed remarkable clinical improvement, with significant FEV1 increase and FeNO reduction, allowing discontinuation of systemic corticosteroids and supplemental oxygen.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Asthma
Journal of Asthma 医学-过敏
CiteScore
4.00
自引率
5.30%
发文量
158
审稿时长
3-8 weeks
期刊介绍: Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信